A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitior
Open Access
- 9 February 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Virology Journal
- Vol. 7 (1), 30
- https://doi.org/10.1186/1743-422x-7-30
Abstract
Influenza is a respiratory disease that seriously threatens human health. In fact, influenza virus itself does not make critical contribution to mortality induced by influenza, but "cytokine storm" produced by the excessive immune response triggered by the virus can result in inflammatory reaction of lung tissues and fatal lung tissue injury, and thus increase influenza mortality. Therefore, besides antiviral drugs, immunosuppression drugs should also be included in infection treatment. Complement is the center of inflammatory reaction. If complement system is over activated, the body will have strong inflammatory reaction or tissue injury, resulting in pathological process. Many studies have proved that, inflammatory injury of lung tissues caused by influenza virus is closely related to complement activation. Therefore, inhibiting complement activation can significantly reduce inflammatory injury in lung tissues. As complement is both a physiological defense and pathological damage medium, systematic inhibition may result in side effects including infection. Therefore, we design targeting complement inhibitors for complement activation sites, i.e. with CR2 as targeting vector, complement inhibitors like CD59 and Crry are targeted to inflammatory sites to specially inhibit the complement activation in local injury, thus local inflammatory reaction is inhibited. CR2-CD59 and CR2-Crry targeting complement inhibitors are fusion-expressed, and their biological activity is examined via in vivo and in vitro tests. CR2 targeting complement inhibitors are used to treat mouse influenza viral pneumonia model, with PBS treatment group as the control. The survival and lung tissue injury of the mice is observed and the effect of CR2 targeting complement inhibitors on pneumonia induced by influenza virus is evaluated. CR2 targeting complement inhibitors are expected to be ideal drugs for viral pneumonia.Keywords
This publication has 27 references indexed in Scilit:
- The NLRP3 Inflammasome Mediates In Vivo Innate Immunity to Influenza A Virus through Recognition of Viral RNAImmunity, 2009
- Distinctly different expression of cytokines and chemokines in the lungs of two H5N1 avian influenza patientsThe Journal of Pathology, 2008
- Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virusProceedings of the National Academy of Sciences of the United States of America, 2008
- Complement–HIV interactions during all steps of viral pathogenesisVaccine, 2008
- CD59a deficiency exacerbates influenza‐induced lung inflammation through complement‐dependent and ‐independent mechanismsEuropean Journal of Immunology, 2007
- Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virusNature, 2007
- 1918 Influenza: the Mother of All PandemicsEmerging Infectious Diseases, 2006
- 1918 Influenza: the Mother of All PandemicsEmerging Infectious Diseases, 2006
- Exogenous ACE2 Expression Allows Refractory Cell Lines To Support Severe Acute Respiratory Syndrome Coronavirus ReplicationJournal of Virology, 2005
- ComplementThe New England Journal of Medicine, 2001